Oppenheimer Asset Management Inc. Acquires Shares of 2,398 Regeneron Pharmaceuticals, Inc. $REGN

Oppenheimer Asset Management Inc. acquired a new stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 2,398 shares of the biopharmaceutical company’s stock, valued at approximately $1,495,000.

Several other large investors also recently modified their holdings of REGN. WPG Advisers LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 312.5% during the 4th quarter. WPG Advisers LLC now owns 33 shares of the biopharmaceutical company’s stock worth $25,000 after buying an additional 25 shares during the period. Western Wealth Management LLC acquired a new position in Regeneron Pharmaceuticals in the 1st quarter valued at about $26,000. SHP Wealth Management bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $26,000. Titan Wealth CI Ltd bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $29,000. Finally, Kemnay Advisory Services Inc. bought a new position in Regeneron Pharmaceuticals in the 4th quarter valued at about $31,000. 83.31% of the stock is owned by institutional investors.

Insider Buying and Selling

In other Regeneron Pharmaceuticals news, Director Huda Y. Zoghbi sold 800 shares of the firm’s stock in a transaction on Monday, August 10th. The stock was sold at an average price of $800.00, for a total transaction of $640,000.00. Following the transaction, the director owned 1,703 shares in the company, valued at $1,362,400. This trade represents a 31.96% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Kathryn Guarini sold 400 shares of Regeneron Pharmaceuticals stock in a transaction on Monday, August 10th. The shares were sold at an average price of $800.00, for a total value of $320,000.00. Following the completion of the transaction, the director directly owned 603 shares of the company’s stock, valued at $482,400. This represents a 39.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 1,400 shares of company stock valued at $1,090,030 over the last 90 days. 6.97% of the stock is owned by corporate insiders.

Regeneron Pharmaceuticals News Roundup

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

• Positive Sentiment: Regeneron is expanding its oncology relationship with Biohaven through a clinical supply agreement to test Biohaven’s BHV-1530 alongside Regeneron’s Libtayo in patients with solid tumors. The combination could strengthen Regeneron’s oncology pipeline if clinical results are favorable. Biohaven-Regeneron Oncology Deal
• Positive Sentiment: Regeneron also entered a strategic research collaboration with Parabilis Medicines to develop antibody-Helicon conjugates. The agreement includes $125 million in upfront consideration and equity investment for Parabilis, with potential milestone payments of up to $2.2 billion plus royalties—highlighting Regeneron’s efforts to broaden its technology base and future pipeline. Parabilis Medicines-Regeneron Collaboration
• Neutral Sentiment: Coverage highlights Regeneron’s exposure to GLP-1-related growth opportunities beyond the leading weight-loss drug makers, although the article provides limited new company-specific financial information. GLP-1 Demand and Regeneron
• Neutral Sentiment: Director Kathryn Guarini sold $320,000 of REGN stock under a pre-arranged Rule 10b5-1 trading plan. Because the sale was scheduled in advance, it is a limited indicator of management’s current outlook.
• Negative Sentiment: Multiple law firms are promoting a securities class action against Regeneron concerning alleged disclosures about the Phase 3 fianlimab-Libtayo melanoma trial. The trial’s failure reportedly erased approximately $11 billion in market value, and the continuing legal notices may keep investor attention focused on potential litigation costs, disclosure risks and weakness in the oncology program. The lead-plaintiff deadline is September 14, 2026. Regeneron Class Action Lawsuit

Regeneron Pharmaceuticals Stock Performance

NASDAQ REGN opened at $803.48 on Monday. The company has a quick ratio of 2.78, a current ratio of 3.34 and a debt-to-equity ratio of 0.06. The company has a market capitalization of $82.73 billion, a P/E ratio of 19.86, a P/E/G ratio of 1.37 and a beta of 0.21. Regeneron Pharmaceuticals, Inc. has a 12-month low of $541.00 and a 12-month high of $821.11. The firm has a 50-day moving average price of $675.79 and a two-hundred day moving average price of $713.99.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its earnings results on Thursday, July 30th. The biopharmaceutical company reported $14.29 EPS for the quarter, topping the consensus estimate of $10.16 by $4.13. Regeneron Pharmaceuticals had a net margin of 27.86% and a return on equity of 13.47%. The company had revenue of $4.29 billion for the quarter, compared to analysts’ expectations of $3.82 billion. During the same period last year, the firm earned $12.81 earnings per share. The business’s revenue for the quarter was up 16.7% on a year-over-year basis. Analysts anticipate that Regeneron Pharmaceuticals, Inc. will post 44.25 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Monday, August 31st. Investors of record on Tuesday, August 18th will be given a dividend of $0.94 per share. The ex-dividend date of this dividend is Tuesday, August 18th. This represents a $3.76 dividend on an annualized basis and a yield of 0.5%. Regeneron Pharmaceuticals’s dividend payout ratio is currently 9.29%.

Analyst Ratings Changes

A number of equities research analysts have recently issued reports on REGN shares. Truist Financial boosted their price objective on Regeneron Pharmaceuticals from $769.00 to $772.00 and gave the stock a “buy” rating in a report on Friday, July 31st. Canaccord Genuity Group lowered their target price on Regeneron Pharmaceuticals from $1,057.00 to $875.00 and set a “buy” rating on the stock in a research note on Tuesday, May 19th. Wells Fargo & Company lifted their price target on Regeneron Pharmaceuticals from $700.00 to $750.00 and gave the stock an “equal weight” rating in a report on Friday, July 31st. Wall Street Zen raised Regeneron Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday. Finally, Barclays reduced their price target on Regeneron Pharmaceuticals from $923.00 to $917.00 and set an “overweight” rating for the company in a research note on Thursday, April 30th. Sixteen research analysts have rated the stock with a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, Regeneron Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average price target of $793.74.

About Regeneron Pharmaceuticals

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.